Sage Journals: Discover world-class research

Abstract

Chronic stress and traumatic events affect the psychological and physiological state of a person. Post-traumatic stress disorder (PTSD) is a type of psychological stress that occurs in critical situations that pose a direct threat to the life of the person and/or his or her loved ones. The prevalence of PTSD is increasing every year due to growing exposure to traumatic factors such as wars, natural disasters, and other crises. These events lead to severe psychological consequences, affecting a rising number of people worldwide. Currently, PTSD can be challenging to treat due to the complex nature of the disorder, variability in individual responses to treatment, and limitations in available therapeutic options. Considering the emergency need for effective PTSD treatment, a drug repurposing strategy presents a promising avenue to accelerate the availability of therapies. Here, we summarized and described drugs that were repurposed for alleviating PTSD symptoms. Moreover, we discussed the potential of some drugs, including alpha-adrenergic modulators, cannabinoids, glutamatergic modulators, and antipsychotics, for being repurposed for PTSD treatment. Drug repurposing implies the rapid identification of compounds with an established safety profile and known therapeutic effects that may be effective in PTSD. Repurposing existing drugs with already established pharmacokinetics and pharmacodynamics may shorten development timelines, facilitate a direct transition to the second phase of clinical trials, and lower costs. However, potential drawbacks and negative aspects should be discussed comprehensively.

Keywords

post-traumatic stress disorder traumatic factor stress treatment drugs

Introduction

Post-traumatic stress disorder (PTSD) is a serious mental condition that may occur in individuals who have experienced traumatic events (TE), such as physical or sexual violence, war, accidents, natural disasters, or other extreme situations.¹ Diagnostic systems were developed to assess PTSD, including the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and the International Classification of Diseases, 11th Edition (ICD-11).² According to DSM-5, there are five specific criteria required for the diagnosis of PTSD, including A – trauma criterion, B – intrusive recollection criterion, C – avoidance criterion, D – negative cognitions and mood criterion, E – alterations in arousal or reactivity criterion.³ The most significant criterion for PTSD diagnosis is experiencing TE.

In accordance with the World Health Organisation, the lifetime prevalence of PTSD is 3.9% of the world population.⁴ Approximately 70% of people worldwide are being subjected to a potential TE at some point in their lives; however, only a small fraction (5.6%) develop PTSD.^4,5 Influence of both external and internal risk factors, such as genetic predisposition, neurophysiological changes and social support, determines development and PTSD severity.⁶ It is worth noting that the prevalence of PTSD increases up to 15.3% in countries with war conflicts.⁷ A recent nationwide cross-sectional study examining stress, anxiety, and PTSD symptoms among Ukrainians revealed that 93% of respondents experienced at least one mental health issue at a moderate or severe level during the first year of the Russian invasion.⁸

PTSD is a multifaceted disorder and includes psychological, neurobiological, and physiological aspects. Dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, hyper-activation of brain structures responsible for stress response, including the amygdala and hippocampus, and chronic inflammation are among the key physiological mechanisms associated with PTSD.^6,9–11

Standard therapeutic approaches for the treatment of PTSD focus on psychotherapy (eg, cognitive behavioural therapy) and the use of pharmacological agents, including antidepressants. Psychotherapy is often unavailable due to high costs or a lack of qualified specialists, and the role of pharmacotherapy has been studied more extensively in recent years. However, many pharmaceuticals have undesirable side effects, which reduce their acceptability to patients.¹² Considering these challenges, recent research has focused on finding new therapeutic approaches based on a deeper understanding of the biological mechanisms of PTSD. In this context, there is a growing interest in repurposing drugs for the treatment of PTSD. Drug repurposing is based on the use of already approved drugs for the treatment of other conditions that have the potential to affect PTSD development.

Although progress has been made in elucidating the neurobiological mechanisms underlying PTSD, effective pharmacological options remain limited. Despite several drugs approved for other diseases showing potential for decreasing PTSD symptoms, the supporting evidence is fragmented and often limited. This highlights the need for a comprehensive review to summarize current knowledge that will assist rational selection of candidates for further preclinical and clinical investigation. This review represents the first effort to comprehensively discuss the effectiveness of some pharmaceutical compounds in alleviating PTSD symptoms. In this review, we summarised current approaches to repurpose medicines for the treatment of PTSD, analysed their potential advantages and limitations, and highlighted the prospects for developing this strategy. Current challenges in PTSD treatment and factors that complicate the search for effective therapeutic solutions are discussed.

Methodology

This narrative review includes summaries of 101 papers to describe compounds that are effective in decreasing PTSD symptoms. A comprehensive literature search was performed to identify relevant studies addressing the potential of some drugs for being repurposed for PTSD treatment. The search was performed in PubMed, Scopus, and Web of Science databases for the period from January 2000 to January 2025. The search strategy combined controlled vocabulary (MeSH terms in PubMed) and free-text keywords. The primary search terms included: “post-traumatic stress disorder” OR “PTSD” OR “treatment” OR “drugs” OR “compound”). Boolean operators (“AND,” “OR”) and truncations were used to maximize sensitivity and specificity. Additional articles were identified by manual screening of reference lists from selected papers. Only articles published in English were considered.

Only research, review articles, and chapters published were included in this study. Studies were included if they: (1) investigated compounds that show effectiveness to decrease PTSD symptoms in preclinical models or clinical trials; (2) provided primary data on molecular, physiological, or behavioral outcomes; and (3) were published in peer-reviewed journals. Exclusion criteria included: (1) conference abstracts, theses, or non-peer-reviewed reports; (2) studies not directly related to the topic of review; and (3) duplicate publications.

Common language editing tools were applied to improve grammar and readability in accordance with academic writing standards.

Drug Repurposing in Psychiatry

One of the promising topics in the current research is the repurposing of existing medicines, also known as drug repositioning, which involves identifying new therapeutic applications for already approved drugs.^13,14 For example, during the COVID-19 pandemic, several drugs were repurposed,¹⁵ including Remdesivir, an antiviral drug developed to treat Ebola,¹⁶ as well as Dexamethasone, a widely used steroid that reduces mortality among hospitalised patients requiring ventilation.¹⁷

The central nervous system (CNS) is a key focus of the research for drug repurposing due to the limited understanding of the pathophysiology and mechanisms of CNS disorders. Many approved drugs for CNS disorders have unclear modes of action, and disease characterisation relies heavily on clinical symptoms rather than biology.¹⁸ Despite high prevalence and unmet needs, CNS drug development has low success rates and longer regulatory approval times.¹⁹

Repurposing of existing pharmacological drugs is a promising area in the treatment of PTSD, as evidenced by the rapid growth in the number of studies in this area. Drug repurposing involves investigating the potential of existing drugs for new therapeutic uses. This strategy is particularly valuable in fields with a historically high risk of failure, such as psychiatry.²⁰ Established safety profiles, cost-effectiveness, accelerated timelines, and expanded treatment options are among the main benefits of a drug repurposing strategy. Already known safety and tolerability profiles entail significantly reduced risks associated with the development process compared to novel drug candidates. Based on publicly available data, it was defined that development costs for new therapeutic agents range from $314 million to $2.8 billion.²¹ Moreover, drug development from original idea to implementation in clinical practice takes 12–15 years,²¹ with an estimated success rate of only 2%.²² Drug repurposing allows for bypassing early-stage development, which makes it a more cost-effective approach.

Drug repurposing is a complex process that includes several stages, including compound selection, compound acquisition, drug development and safety monitoring.²³ Drug-oriented, disease-oriented and target-oriented are three main approaches to drug repurposing.²³ A drug-oriented approach expands the application of an already approved drug. The disease-oriented approach is especially valuable for rare diseases and involves the identification of the diseases with homologous underlying biological mechanisms to the indication the original drug treats. Investigating the specific molecular targets implicated in a disease's pathology involves a target-oriented approach.

Many psychiatric disorders, such as depression, bipolar disorder, schizophrenia, and certain anxiety disorders, have limited effective pharmacological treatments. This raises an urgent need for innovative strategies to expand therapeutic options. Existing compounds were suggested to be effective in alleviating various CNS conditions. Ketamine, originally developed as an anaesthetic, has been successfully repurposed for treatment-resistant depression.^24,25 Ketamine exerts rapid antidepressant effects through N-methyl-D-aspartate (NMDA) receptor antagonism and does not cause adverse effects.²⁶ Similarly, lithium has been used for gout and other medical conditions and was proven to be effective in the treatment of bipolar disorder.²⁷ The mood-stabilising properties of lithium are associated with its neurotrophic properties, which affect several molecular targets, including neurotrophins, glycogen synthase kinase 3 (GSK-3), and key proteins of the mitochondrial/endoplasmic reticulum.²⁸ Another example of drug repurposing in psychiatry is modafinil, which has been initially approved for narcolepsy, and recently investigated as an adjunctive treatment for major depressive disorder (MDD)²⁹ and schizophrenia.^30,31 Antiepileptic drugs, lamotrigine and valproate, were effectively used for mood stabilisation in bipolar disorder.^32,33 Atypical antipsychotics such as aripiprazole and quetiapine, initially used to treat schizophrenia, are now extensively used for depression and anxiety disorders.^34,35

The drug repurposing approach presents several challenges, including the need to reevaluate dosage, long-term effects, and regulatory considerations for new indications. Nevertheless, the cost-effectiveness and faster development timelines make drug repurposing an attractive option, particularly in the context of increasing mental health issues globally. Psychological disorders often have complex and multifactorial mechanisms involving genetic, neurochemical, and environmental factors. To repurpose drugs for the treatment of psychological disorders, the detailed pathophysiology of these conditions should be studied.

Repurposing Existing Drugs for PTSD Therapy

Understanding the neurobiology of PTSD accelerates the development of effective pharmacotherapy. Post-traumatic stress disorder is a multidimensional disorder that combines a wide range of neurobiological changes, including disturbances of the hypothalamic-pituitary-adrenal gland axis, hyperactivation of the amygdala, and disruption of some hippocampal and cortical functions.^36,37 Stress leads to an elevated release of stress hormones such as adrenaline and epinephrine into the bloodstream, initiating changes in the brain and triggering the stress response.³⁸ One of the key players in this stress response is corticotropin-releasing hormone (CRH), which is secreted by neurons in the paraventricular nucleus of the hypothalamus. CRH stimulates the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland.^39,40 ACTH moves through the bloodstream to the adrenal glands, prompting the release of cortisol. Cortisol plays a crucial role in regulating metabolic and immune functions, contributing to the overall stress response. Targeting cortisol levels and function could help alleviate the physiological and emotional symptoms of PTSD.

The renin-angiotensin-aldosterone (RAA) system is involved in the stress response and works in tandem with the HPA axis to regulate physiological and metabolic processes during stress. Stress-induced increase in the levels of angiotensin results in activation of the HPA axis and an increase in circulating cortisol.⁴¹ Conversely, ACTH induces aldosterone secretion.⁴² Overactivation of RAA system contributes to neuroinflammation and oxidative stress, which are associated with PTSD pathophysiology.⁴³ High aldosterone levels may cause depressive and anxiety-related behavior through direct impacts on brain regions, including the amygdala and prefrontal cortex.⁴⁴ Stress activates the sympathetic nervous system (SNS) and triggers the release of renin into the bloodstream. Renin converts angiotensinogen into angiotensin I, which is then converted into angiotensin II by angiotensin-converting enzyme (ACE).⁴⁵ Angiotensin II enhances the activity of the HPA axis,⁴⁶ playing a central role in the stress response in PTSD.

Neurotransmitter systems play a critical role in PTSD severity and represent key targets for drug therapy. Dysregulation of serotonin in PTSD is associated with heightened anxiety, aggression and depression.⁴⁷ Serotonin reuptake inhibitors (SSRIs) work by inhibiting the reuptake of serotonin and increasing serotonin levels in the brain, leading to a reduction of PTSD severity. Dopamine dysfunction is increasingly recognised as a contributing factor to the symptoms of anhedonia and emotional numbing commonly seen in PTSD.⁴⁸ Glutamate and glutamatergic systems are implicated in synaptic plasticity and fear learning. Increased blood glutamate levels are closely associated with mood disorders.^49–51 Drugs targeting the glutamatergic systems could be effective in alleviating PTSD symptoms.

SSRIs paroxetine and sertraline had been initially used to treat depression and anxiety disorders.⁵² Currently, paroxetine and sertraline are the only drugs approved by the Food and Drug Administration as first-line treatments for PTSD.⁵³ The therapeutic actions of SSRIs are associated with the enhancement of serotonin levels that are decreased under stress or depression (Table 1).⁵⁴ SSRIs work by blocking the serotonin transporter (SERT) located at the presynaptic axon terminal. This inhibition prevents serotonin (5-hydroxytryptamine, or 5-HT) reabsorption by presynaptic neurons. As a result, serotonin accumulates in the synaptic cleft, allowing it to activate postsynaptic receptors for a more extended period.⁵⁵ Enhancement of the serotonergic neurotransmission causes improvement of mood, anxiety, and sleep.⁵⁶

Table 1.

Existed Drugs That Show Effectiveness in Alleviation PTSD Symptoms.

Drug	Original Use	Beneficial effects on PTSD symptoms	Ref
Paroxetine	Depression and anxiety	decreases intrusive memories, flashbacks, and irritability, alleviates avoidance behaviors, decreases anxiety and depression	[^90,91]
Sertraline	Depression and anxiety	decreases intrusive memories, flashbacks, and irritability, alleviates avoidance behaviors, decreases anxiety and depression	[⁹²]
Dronabinol	Nausea and vomiting caused by cancer treatment	improves sleep quality and decreases hyperarousal	[⁵⁷]
Clonidine	Hypertension	alleviates sleep disturbances and nightmares; decreases overall PTSD symptoms	[⁵⁸]
Doxazosin	Hypertension	alleviates sleep disturbances and nightmares; decreases overall PTSD symptoms	[^64–67]
Propranolol	Hypertension, anxiety, and migraine	decreases the intensity of intrusive memories, flashbacks, nightmares and hyperarousal	[⁶⁸]
Prazosin	Hypertension	alleviates sleep disturbances and nightmares; decreases overall PTSD symptoms	[^72–74]
Ketamine	Anesthetic	decreases depression and overall PTSD symptoms	[⁷⁹]
Risperidone	Schizophrenia and bipolar disorder	improves the psychiatric symptoms of PTSD	[⁸¹]
Quetiapine	Schizophrenia and bipolar disorder	treats hyperarousal and reexperience disorder; reduces flashbacks	[^83–85]
Lamotrigine	Epilepsy	decreases reexperiencing and avoidance/numbing symptoms	[⁸⁶]
Valproate	Epilepsy and bipolar disorder	decreases hyperarousal, irritability, and mood disturbances	[^88,89]
Minocycline	Antibiotic	reduces mood symptoms of PTSD	[⁹³]
Metformin	Type 2 diabetes	reduces symptoms of PTSD	[^94,95]
Hydrocortisone	Adrenocortical insufficiency	reduces symptoms of depression and PTSD	[^96,97]

The study of existing cannabinoid drugs [NCT04448808] led by Charité University was focused on the effectiveness of dronabinol in overcoming nightmares caused by PTSD.⁵⁷ Dronabinol modulates the endocannabinoid system, which influences emotional regulation, fear extinction, and sleep. Preliminary evidence from open-label and small-scale trials suggested significant improvements in nightmare frequency, sleep quality, and hyperarousal symptoms.⁵⁷

A study [NCT04877093] conducted by the Minneapolis Veterans Affairs Healthcare System investigated the effectiveness of low-dose clonidine for the treatment of PTSD in veterans who often have PTSD.^58,59 Clonidine, an alpha-2 adrenergic agonist, showed promise in improving PTSD symptoms, particularly sleep disturbances and nightmares. It was reported that significant improvements in symptoms occurred for doses above 0.1 mg/day, with 49–85% of patients experiencing partial or marked relief.⁵⁸ Mild side effects, including grogginess and dizziness, were reported in 23% of patients.⁵⁸ Clonidine acts centrally to inhibit norepinephrine release with subsequent inhibition of sympathetic overactivation associated with PTSD.⁶⁰ Moreover, clonidine can stabilise adrenergic activity and lead to improved mood and a reduction of aggressive behaviours.⁶¹

Doxazosin was approved for the treatment of hypertension as well as urinary tract obstruction, and was shown to be effective in reducing PTSD symptoms⁶² and may also be used for comorbid PTSD and alcohol use disorders.⁶³ Improved sleep quality and decreased frequency and intensity of trauma-related nightmares were documented in combat veterans with PTSD after 8 weeks of treatment with 4 mg/day of doxazosin.⁶⁴ The study by Rodgman and colleagues⁶⁵ showed alleviation of PTSD symptoms after four days of treatment with 16 mg/day of doxazosin. The efficiency of doxazosin for PTSD was also proven in several studies.^66,67

Propranolol, used initially for the treatment of hypertension, anxiety, and migraine prevention, was repurposed for reducing the emotional intensity of traumatic memories associated with PTSD.⁶⁸ Propranolol acts as a non-selective beta-adrenergic blocker to reduce overactivation of the sympathetic nervous system caused by stress.⁶⁹ However, some controversial studies showed that posttrauma propranolol treatment had no efficacy for preventing subsequent PTSD⁷⁰ or did not reduce PTSD incidence.⁷¹

A repurposed anti-hypertensive drug, prazosin, was shown to be beneficial for treating PTSD symptoms.^72–74 By blocking alpha-1 adrenergic receptors, prazosin improves sleep quality and reduces nightmares and PTSD symptoms.⁷⁵

Ketamine had been approved initially as a general anaesthetic and was repurposed for several other disorders, including depressive disorders, suicidal ideation, substance-use disorders, anxiety disorders, and bronchial asthma complications.⁷⁶ The beneficial effects of ketamine on mental health are realised via inhibition of NMDA receptors⁷⁷ and regulation of glutamate pathways.⁷⁸ A randomised controlled trial involving 30 individuals with chronic PTSD showed that the ketamine-treated group showed significant improvement in PTSD symptoms and depression.⁷⁹

Primarily used to treat schizophrenia and bipolar disorder, risperidone and quetiapine have shown potential in addressing PTSD symptoms.^80,81 The effects of low-dose risperidone on aggression and PTSD symptoms in male combat veterans with PTSD were previously evaluated.⁸¹ In this study, risperidone significantly reduced irritability and intrusive thoughts, suggesting its potential efficacy in managing these PTSD-related symptoms.⁸¹ The beneficial effects of risperidone in PTSD are associated with the regulation of the dopaminergic system and HPA axis.⁸² Quetiapine is recommended for persons with PTSD to decrease symptoms of hyperarousal and re-experience disorder.^83,84 Moreover, the combination therapy with quetiapine, SSRI and gabapentin significantly reduced flashbacks.⁸⁵

Anticonvulsants, including lamotrigine and valproate, were found to be effective for the treatment of PTSD. Treatment with lamotrigine leads to improvement in reexperiencing and avoidance/numbing symptoms in both combat and civilian PTSD.⁸⁶ Lamotrigine inhibits voltage-gated sodium channels, reduces glutamate release in the brain, and inhibits overactivation of the amygdala.⁸⁷ Valproate shows potential for the treatment of PTSD by mitigating symptoms such as hyperarousal, irritability, and mood disturbances.^88,89 It acts by increasing GABAergic activity and reducing glutamatergic excitotoxicity, addressing neural hyperactivity and stress-related neuroplastic changes observed in PTSD.^88,89

Targeting biological pathways involved in PTSD with pharmaceutical components may be promising for investigating new approaches for its treatment. Inflammation was shown to play a key role in the pathogenesis and pathophysiology of PTSD.^9,10 Anti-inflammatory drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and cytokine inhibitors, could show promise in PTSD treatment based on their mechanisms of action. Statins may potentially help reduce neuroinflammation and cognitive decline associated with PTSD. To prevent or treat PTSD, common antibiotics with neuroprotective and anti-inflammatory effects may be effective. An example is minocycline, which passed phase IV of clinical trials, and its treatment is associated with reduced inflammation and reduced mood symptoms of PTSD.⁹³ Corticosteroid hydrocortisone, which is used for replacement therapy in primary, secondary, or acute adrenocortical insufficiency, showed promising effects in alleviating PTSD symptoms.^94,95 Decreased intensity of chronic stress and PTSD symptoms at 6 months after traumatic event (cardiac surgery) was shown in patients exposed to hydrocortisone treatment.⁹⁶ A randomised double-blind trial showed that low-dose hydrocortisone treatment results in fewer PTSD and depression symptoms.⁹⁵ Moreover, the antibiotic rapamycin may be used as a treatment for anxiety disorders.⁹⁶

Metformin, initially approved for the treatment of Type 2 diabetes, was later shown to be effective in antiviral treatments.^97,98 It was also able to decrease PTSD symptoms in both PTSD animal⁹⁹ and veterans.¹⁰⁰ Metformin activates the 5′-adenosine monophosphate-activated protein kinase (AMPK) pathway, attenuates oxidative stress and preserves mitochondrial function in the hippocampus of rat models of PTSD.⁹⁹

Challenges and Limitations of Drug Repurposing for PTSD

The process of drug repurposing is often considered to be a highly advantageous strategy; however, potential drawbacks and negative aspects should be discussed comprehensively (Figure 1). Within the area of PTSD, drug repurposing presents several challenges and limitations. The complexity of PTSD pathophysiology, with neurobiological and psychological aspects, significantly complicates the identification of repurposed drugs. PTSD pathophysiology is associated with alterations in multiple systems, including the HPA axis, the serotonergic and dopaminergic pathways, and inflammation-related processes.^9,10 Considering the multifaceted nature of PTSD, identifying a drug that can comprehensively address these diverse mechanisms is challenging.

Figure 1.

Representations of Benefits and Challenges of Drug Repurposing for PTSD Treatment.

High comorbidity of PTSD with other psychiatric and physical health conditions, such as depression, anxiety disorders, substance use disorders, and cardiovascular diseases,¹⁰¹ makes drug repurposing challenging. Indeed, treatments for PTSD may interact with medications prescribed for co-occurring conditions.

Additional limitations for drug repurposing may be caused by the heterogeneity of PTSD symptoms across individuals. A repurposed drug may be effective for one subset of symptoms and may not work for others. Moreover, drugs used to treat a particular disorder may exhibit one set of side effects, but those used to treat another disease may show completely different side effects. Consequently, the potential safety risks and side effects when using drugs outside their approved indications, particularly in vulnerable PTSD populations, should be tested. Addressing all these limitations requires a multidisciplinary approach that integrates insights from neuroscience, pharmacology, and clinical practice.

Conclusion and Future Directions

Drug repurposing is a promising and cost-effective strategy for the development of new therapeutic approaches for PTSD. Applying a drug repurposing strategy allows for saving costs and expediting the drug development process. Using existing data on approved or investigational drugs within a drug repurposing strategy significantly reduces the time and costs associated with early-stage research and preclinical trials. Moreover, drug repurposing facilitates the development of combination therapies that address multiple aspects of PTSD pathophysiology, potentially providing more comprehensive and effective treatment options.

Despite these advantages, several challenges must be carefully addressed to maximise the success of this strategy. Potential obstacles include a limited understanding of PTSD heterogeneity, the need for robust clinical validation, possible off-target effects, and regulatory hurdles in repurposing drugs for new indications. Overcoming these challenges requires interdisciplinary collaboration and integration of advanced technologies and high-throughput screening methods.

Future research phase III clinical trials should prioritize alpha-adrenergic modulators, cannabinoids, glutamatergic modulators, and antipsychotics, given their demonstrated potential to alleviate core symptoms of PTSD. Furthermore, a key direction for future research is the application of precision medicine in PTSD treatment. Tailoring drug repurposing efforts based on individual patient profiles, including genetic factors and severity of symptoms, might be addressed by precision medicine in the context of PTSD. Genetic variations play a crucial role in shaping individual susceptibility to PTSD and treatment response. Additionally, considering the heterogeneity of PTSD symptoms, precision medicine approaches may help identify the most suitable repurposed drugs for different symptom clusters, ultimately leading to more personalised and targeted interventions. Consequently, further research is essential to optimise its implementation, address existing limitations, and ensure its successful integration into clinical practice.

As a narrative review, this work does not follow the complete set of guidelines of a systematic review, which may introduce limitations such as selection bias. Furthermore, the absence of meta-analytic synthesis restricts quantitative comparison across studies. Nonetheless, by critically integrating existing preclinical and clinical findings, the review provides an integrated overview and highlights key directions for future research.

Footnotes

List of abbreviations

ORCID iD

Oleh Lushchak

Ethics Approval and Consent to Participate

This article is a literature review and does not involve human participants or primary data collection. Therefore, ethical approval and consent to participate declarations are not applicable.

Consent for Publication

Not applicable.

Author Contributions

OL led the development and writing of the manuscript. OS contributed to the literature search, data extraction for the table, and writing the manuscript. OL and OS reviewed and provided feedback. All authors approved the final manuscript.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a grant from the Ministry of Education and Science of Ukraine [grant number 0125U000396].

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

Diao

Zhou

, et al. Post-traumatic stress disorder: A psychiatric disorder requiring urgent attention. Med Rev. (2021). 2022;2(3):219-243.

Hansen

Armour

McGlinchey

, et al. Investigating the DSM-5 and the ICD-11 PTSD symptoms using network analysis across two distinct samples. Psychol Trauma. 2023;15(5):757-766.

Pai

Suris

North

. Post-traumatic stress disorder in the DSM-5: Controversy, change, and conceptual considerations. Behav Sci (Basel). 2017;7(1):7.

Koenen

Ratanatharathorn

, et al. Post-traumatic stress disorder in the world mental health surveys. Psychol Med. 2017;47(13):2260-2274.

Kessler

Aguilar-Gaxiola

Alonso

, et al. Trauma and PTSD in the WHO world mental health surveys. Eur J Psychotraumatol. 2017;8(sup5):1353383.

Sherin

Nemeroff

. Post-traumatic stress disorder: The neurobiological impact of psychological trauma. Dialogues Clin Neurosci. 2011;13(3):263-278.

Charlson

van Ommeren

Flaxman

, et al. New WHO prevalence estimates of mental disorders in conflict settings: A systematic review and meta-analysis. Lancet. 2019;394(10194):240-248.

Lushchak

Velykodna

Bolman

, et al. Prevalence of stress, anxiety, and symptoms of post-traumatic stress disorder among Ukrainians after the first year of Russian invasion: A nationwide cross-sectional study. Lancet Reg Health Eur. 2023;36:100773.

Lushchak

Orru

Strilbytska

, et al.

Metabolic and immune dysfunctions in post-traumatic stress disorder: What can we learn from animal models?

EXCLI J. 2023;22:928-945.

10.

Dmytriv

Tsiumpala

Semchyshyn

, et al. Mitochondrial dysfunction as a possible trigger of neuroinflammation at post-traumatic stress disorder (PTSD). Front Physiol. 2023;14:1222826.

11.

Serhiyenko

Holzmann

Holota

, et al. An exploratory study of physiological and biochemical parameters to identify simple, robust and relevant biomarkers for therapeutic interventions for ptsd: study rationale, key elements of design and a context of war in Ukraine. Proc Shevchenko Sci Soc Med Sci [Internet]. 2022;69(2).

12.

Pawar

Wiegand

. Monoamine oxidase inhibitors. In: Wexler

, ed. Encyclopedia of Toxicology (Fourth Edition). Academic Press; 2024:499-502.

13.

Zhan

Ouyang

. Drug repurposing: An effective strategy to accelerate contemporary drug discovery. Drug Discov Today. 2022;27(7):1785-1788.

14.

Vaiserman

Koliada

Lushchak

Castillo

. Repurposing drugs to fight aging: The difficult path from bench to bedside. Med Res Rev. 2021;41(3):1676-1700.

15.

Bakowski

Beutler

Wolff

, et al. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat Commun. 2021;12(1):3309.

16.

Beigel

Tomashek

Dodd

, et al. Remdesivir for the treatment of COVID-19. Final Report. N Engl J Med. 2020;383(19):1813-1826.

17.

Martinez-Guerra

Gonzalez-Lara

Roman-Montes

, et al. Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: A prospective cohort study. Emerg Microbes Infect. 2022;11(1):50-59.

18.

Hardman

Limbird

Molinoff

. Goodman & Gilman’s the Pharmacological Basis of Therapeutics: Section III Chapter 12 Neurotransmission and the Central Nervous System. 11th. McGraw-Hill; 2008:265-578.

19.

Pangalos

Schechter

Hurko

. Drug development for CNS disorders: Strategies for balancing risk and reducing attrition. Nat Rev Drug Discov. 2007;6(7):521-532.

20.

Fava

. The promise and challenges of drug repurposing in psychiatry. World Psychiatry. 2018;17(1):28-29.

21.

Wouters

McKee

Luyten

. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323(9):844-553.

22.

Yeu

Yoon

Park

. Protein localisation vector propagation: A method for improving the accuracy of drug repositioning. Mol BioSyst. 2015;11:2096-2102.

23.

Xue

Xie

Wang

. Review of drug repositioning approaches and resources. Int J Biol Sci. 2018;14(10):1232-1244.

24.

Carboni

Carta

Carboni

Novelli

. Repurposing ketamine in depression and related disorders: Can this enigmatic drug achieve success? Front Neurosci. 2021;15:657714.

25.

Serafini

Howland

Rovedi

, et al. The role of ketamine in treatment-resistant depression: A systematic review. Curr Neuropharmacol. 2014;12(5):444-461.

26.

Strasburger

Bhimani

Kaabe

, et al. What is the mechanism of ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. J Clin Pharm Ther. 2017;42(2):147-154.

27.

O'Connell

Mayo

Flatow

, et al. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry. 1991;159:123-129.

28.

Machado-Vieira

Manji

Zarate Jr

. The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 2009;11(Suppl 2):92-109.

29.

Fava

Thase

DeBattista

. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1):85-93.

30.

Scoriels

Jones

Sahakian

. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology. 2013;64:168-184.

31.

Lees

Michalopoulou

Lewis

, et al. Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: The effects of test battery in a randomised controlled trial. Psychol Med. 2017;47(13):2358-2368.

32.

Ginsberg

. Efficacy and safety of lamotrigine for adults with bipolar disorder in a private practice setting. CNS Spectr. 2006;11:376-382.

33.

Manning

. Valproate in bipolar disorder: Case examples from a family practice. Prim Care Companion J Clin Psychiatry. 1999;1(3):71-73.

34.

Shapiro

Renock

Arrington

, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-1411.

35.

Chessick

Allen

Thase

, et al. Azapirones for generalised anxiety disorder. Cochrane Database Syst Rev. 2006;2006(3):CD006115.

36.

Malikowska-Racia

Salat

. Recent advances in the neurobiology of post-traumatic stress disorder: A review of possible mechanisms underlying an effective pharmacotherapy. Pharmacol Res. 2019;142:30-49.

37.

Heim

Nemeroff

. Neurobiology of post-traumatic stress disorder. CNS Spectr. 2009;14(1 Suppl 1):13-24.

38.

Goldstein

. Adrenal responses to stress. Cell Mol Neurobiol. 2010;30(8):1433-1440.

39.

Hadad

Schwendt

Knackstedt

. Hypothalamic-pituitary-adrenal axis activity in post-traumatic stress disorder and cocaine use disorder. Stress. 2020;23(6):638-650.

40.

Leistner

Menke

. Hypothalamic-pituitary-adrenal axis and stress. Handb Clin Neurol. 2020;175:55-64.

41.

Grippo

Johnson

. Stress, depression and cardiovascular dysregulation: A review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress Amst Neth. 2009;12:1-21.

42.

El Ghorayeb

Bourdeau

Lacroix

. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Front Endocrinol. 2016;7:72.

43.

Mirzahosseini

Ismael

Ahmed

Ishrat

. Manifestation of renin angiotensin system modulation in traumatic brain injury. Metab Brain Dis. 2021;36(6):1079-1086.

44.

Murck

Schlageter

Schneider

, et al. The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression - lessons from primary aldosteronism. J Psychiatr Res. 2020;130:82-88.

45.

Seligowski

Duffy

Merker

, et al. The renin-angiotensin system in PTSD: A replication and extension. Neuropsychopharmacology. 2021;46(4):750-755.

46.

Calogero

Fornito

Aliffi

, et al. Role of peripherally infused angiotensin II on the human hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf). 1991;34(3):183-186.

47.

Southwick

Paige

Morgan 3rd

, et al. Neurotransmitter alterations in PTSD: Catecholamines and serotonin. Semin Clin Neuropsychiatry. 1999;4(4):242-248.

48.

Lokshina

Nickelsen

Liberzon

. Reward processing and circuit dysregulation in post-traumatic stress disorder. Front Psychiatry. 2021;12:559401.

49.

Averill

Purohit

Averill

, et al. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neurosci Lett. 2017;649:147-155.

50.

Shen

Tomar

. Elevated brain glutamate levels in bipolar disorder and pyruvate carboxylase-mediated anaplerosis. Front Psychiatry. 2021;12:640977.

51.

Inoshita

Umehara

Watanabe

, et al. Elevated peripheral blood glutamate levels in major depressive disorder. Neuropsychiatr Dis Treat. 2018;14:945-953.

52.

Kent

Coplan

Gorman

. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry. 1998;44(9):812-824.

53.

Alexander

. Pharmacotherapy for post-traumatic stress disorder in combat veterans: Focus on antidepressants and atypical antipsychotic agents. P T. 2012;37(1):32-38.

54.

Stahl

. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215-235.

55.

Xue

Wang

, et al. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: An insight from molecular dynamics simulation study. Phys Chem Chem Phys. 2016;18(4):3260-3271.

56.

Lin

Liu

Guan

, et al. Latest updates on the serotonergic system in depression and anxiety. Front Synaptic Neurosci. 2023;15:1124112.

57.

Roepke

Schoofs

Priebe

, et al. Treating nightmares in post-traumatic stress disorder with dronabinol: Study protocol of a multicenter randomised controlled study (THC PTSD-trial). BMC Psychiatry. 2023;23(1):319.

58.

Burek

Waite

Heslin

, et al. Low-dose clonidine in veterans with post-traumatic stress disorder. J Psychiatr Res. 2021;137:480-485.

59.

Detweiler

Pagadala

Candelario

, et al. Treatment of post-traumatic stress disorder nightmares at a veterans affairs medical center. J Clin Med. 2016;5(12):117.

60.

Marazziti

Carmassi

Cappellato

, et al. Novel pharmacological targets of post-traumatic stress disorders. Life (Basel). 2023;13(8):1731.

61.

Giovannitti Jr

Thoms

Crawford

. Alpha-2 adrenergic receptor agonists: A review of current clinical applications. Anesth Prog. 2015;62(1):31-39.

62.

Richards

Inslicht

Ruoff

, et al. An open-label study of doxazosin extended-release for PTSD: Findings and recommendations for future research on doxazosin. Focus (Am Psychiatr Publ). 2018;16(1):67-73.

63.

Back

Flanagan

Jones

, et al. Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomised controlled trial in military veterans. Contemp Clin Trials. 2018;73:8-15.

64.

Sethi

Vasudeva

. Doxazosin for the treatment of nightmares: Does it really work? A case report. Prim Care Companion CNS Disord. 2012;14(5):PCC.12l01356.

65.

Rodgman

Verrico

Holst

, et al. Doxazosin XL reduces symptoms of post-traumatic stress disorder in veterans with PTSD: A pilot clinical trial. J Clin Psychiatry. 2016;77(5):e561-e565.

66.

De Jong

Wauben

Huijbrechts

, et al. Doxazosin treatment for post-traumatic stress disorder. J Clin Psychopharmacol. 2010;30(1):84-85.

67.

Roepke

Danker-Hopfe

Repantis

, et al. Doxazosin, an α-1-adrenergic-receptor antagonist, for nightmares in patients with post-traumatic stress disorder and/or borderline personality disorder: A chart review. Pharmacopsychiatry. 2017;50(1):26-31.

68.

Raut

Canales

Ravindran

, et al. Effects of propranolol on the modification of trauma memory reconsolidation in PTSD patients: A systematic review and meta-analysis. J Psychiatr Res. 2022;150:246-256.

69.

Mueller

Ayres

. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man. J Clin Invest. 1980;65(2):338-346.

70.

Hoge

Worthington

Nagurney

, et al. Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. CNS Neurosci Ther. 2012;18(1):21-27.

71.

Argolo

Cavalcanti-Ribeiro

Netto

Quarantini

. Prevention of post-traumatic stress disorder with propranolol: A meta-analytic review. J Psychosom Res. 2015;79(2):89-93.

72.

Peskind

Bonner

Hoff

Raskind

. Prazosin reduces trauma-related nightmares in older men with chronic post-traumatic stress disorder. J Geriatr Psychiatry Neurol. 2003;16:165-171.

73.

Raskind

Dobie

Kanter

, et al. The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with post-traumatic stress disorder: A report of 4 cases. J Clin Psychiatry. 2000;61:129-134.

74.

Ahmadpanaha

Sabzeieea

Hosseini

, et al. Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from post-traumatic stress disorder. Neuropsychobiology. 2014;69:235-242.

75.

Taylor

Raskind

. The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma post-traumatic stress disorder. J Clin Psychopharmacol. 2002;22(1):82-85.

76.

Gautam

Mahajan

Sharma

, et al. Repurposing potential of ketamine: Opportunities and challenges. Indian J Psychol Med. 2020;42(1):22-29.

77.

Zorumski

Izumi

Mennerick

. Ketamine: NMDA receptors and beyond. J Neurosci. 2016;36(44):11158-11164.

78.

Chowdhury

Behar

Cho

, et al. ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol Psychiatry. 2012;71(11):1022-1025.

79.

Feder

Costi

Rutter

, et al. A randomised controlled trial of repeated ketamine administration for chronic post-traumatic stress disorder. Focus (Am Psychiatr Publ). 2023;21(3):296-305.

80.

Villarreal

Hamner

Qualls

Cañive

. Characterising the effects of quetiapine in military post-traumatic stress disorder. Psychopharmacol Bull. 2018;48(2):8-17.

81.

Monnelly

Ciraulo

Knapp

Keane

. Low-dose risperidone as adjunctive therapy for irritable aggression in post-traumatic stress disorder. J Clin Psychopharmacol. 2003;23(2):193-196.

82.

Krishnamurthy

Garabadu

Joy

. Risperidone ameliorates post-traumatic stress disorder-like symptoms in modified stress re-stress model. Neuropharmacology. 2013;75:62-77.

83.

Sattar

Ucci

Grant

, et al. Quetiapine therapy for post-traumatic stress disorder. Ann Pharmacother. 2002;36(12):1875-1878.

84.

Hamner

Deitsch

Brodrick

, et al. Quetiapine treatment in patients with post-traumatic stress disorder: An open trial of adjunctive therapy. J Clin Psycho-Pharmacol. 2003;23:15-20.

85.

Filteau

Leblanc

Bouchard

. Quetiapine reduces flashbacks in chronic post-traumatic stress disorder. Can J Psychiatry. 2003;48:282-283.

86.

Hertzberg

Butterfield

Feldman

, et al. A preliminary study of lamotrigine for the treatment of post-traumatic stress disorder. Biol Psychiatry. 1999;45(9):1226-1229.

87.

Costa

Vale

. Understanding lamotrigine's role in the CNS and possible future evolution. Int J Mol Sci. 2023;24(7):6050.

88.

Petty

Davis

Nugent

, et al. Valproate therapy for chronic, combat-induced post-traumatic stress disorder. J Clin Psychopharmacol. 2002;22(1):100-101.

89.

Otte

Wiedemann

Yassouridis

Kellner

. Valproate monotherapy in the treatment of civilian patients with non-combat-related post-traumatic stress disorder: An open-label study. J Clin Psychopharmacol. 2004;24(1):106-108.

90.

Marshall

Beebe

Oldham

Zaninelli

. Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. Am J Psychiatry. 2001;158(12):1982-1988.

91.

Kucukalić

Bravo-Mehmedbasić

Dzubur-Kulenović

. Paroxetine in the treatment of post traumatic stress disorder: Our experiences. Bosn J Basic Med Sci. 2008;8(1):76-79.

92.

Brady

Pearlstein

Asnis

, et al. Efficacy and safety of sertraline treatment of post-traumatic stress disorder: A randomised controlled trial. JAMA. 2000;283(14):1837-1844.

93.

Gerst

Murthy

Elson

, et al. Adjunctive minocycline for treatment of post-traumatic stress disorder. WMJ. 2021;120(4):321-324.

94.

Schelling

Kilger

Roozendaal

, et al. Stress doses of hydrocortisone, traumatic memories, and symptoms of post-traumatic stress disorder in patients after cardiac surgery: A randomised study. Biol Psychiatry. 2004;55(6):627-633.

95.

Delahanty

Gabert-Quillen

Ostrowski

, et al. The efficacy of initial hydrocortisone administration at preventing post-traumatic distress in adult trauma patients: A randomised trial. CNS Spectr. 2013;18(2):103-111.

96.

MacCallum

Cooze

Ward

, et al. Evaluating the effects of single, multiple, and delayed systemic rapamycin injections to contextual fear reconsolidation: Implications for the neurobiology of memory and the treatment of PTSD-like reexperiencing. Behav Brain Res. 2024;461:114855.

97.

Halabitska

Petakh

Lushchak

, et al. Metformin in antiviral therapy: Evidence and perspectives. Viruses. 2024;16(12):1938.

98.

Kamyshnyi

Matskevych

Lenchuk

, et al. Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential. Biomed Pharmacother. 2021;144:112230.

99.

Wang

Xiao

Han

Shi

. Metformin alleviated the neuronal oxidative stress in hippocampus of rats under single prolonged stress. J Mol Neurosci. 2017;63(1):28-35.

100.

Liu

Raines

Yoshida

, et al. 174-LB: Association between metformin treatment and improved symptoms of post-traumatic stress disorder. Diabetes. 2020;69:174-LB.

101.

Brady

Killeen

Brewerton

Lucerini

. Comorbidity of psychiatric disorders and post-traumatic stress disorder. J Clin Psychiatry. 2000;61(Suppl 7):22-32.

Repurposing Existing Drugs for the Treatment of Post-Traumatic Stress Disorder

Abstract

Keywords

Introduction

Methodology

Drug Repurposing in Psychiatry

Repurposing Existing Drugs for PTSD Therapy

Challenges and Limitations of Drug Repurposing for PTSD

Conclusion and Future Directions

Footnotes

List of abbreviations

ORCID iD

Ethics Approval and Consent to Participate

Consent for Publication

Author Contributions

Funding

Declaration of Conflicting Interests

References